Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.

Mountzios G, Lammers PE, Sun L, Cho BC, Demirci U, Arulananda S, Gumus M, Punekar S, Lugini A, Zhu B, Yu Y, Ciuleanu TE, Ahn MJ, Mazieres J, Schuler M, Blackhall F, Yoshida T, Dirnberger F, Wang J, Huang S, Gauto D, Rudin CM

Open source

DOI: 10.1016/j.lungcan.2026.109581
Published: 2026 Oct
Container: Lung cancer (Amsterdam, Netherlands)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2026.109581,
  title = {Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.},
  author = {Mountzios G and Lammers PE and Sun L and Cho BC and Demirci U and Arulananda S and Gumus M and Punekar S and Lugini A and Zhu B and Yu Y and Ciuleanu TE and Ahn MJ and Mazieres J and Schuler M and Blackhall F and Yoshida T and Dirnberger F and Wang J and Huang S and Gauto D and Rudin CM},
  year = {2026},
  journal = {Lung cancer (Amsterdam, Netherlands)},
  doi = {10.1016/j.lungcan.2026.109581},
  url = {https://doi.org/10.1016/j.lungcan.2026.109581}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.
AU  - Mountzios G
AU  - Lammers PE
AU  - Sun L
AU  - Cho BC
AU  - Demirci U
AU  - Arulananda S
AU  - Gumus M
AU  - Punekar S
AU  - Lugini A
AU  - Zhu B
AU  - Yu Y
AU  - Ciuleanu TE
AU  - Ahn MJ
AU  - Mazieres J
AU  - Schuler M
AU  - Blackhall F
AU  - Yoshida T
AU  - Dirnberger F
AU  - Wang J
AU  - Huang S
AU  - Gauto D
AU  - Rudin CM
PY  - 2026
JO  - Lung cancer (Amsterdam, Netherlands)
DO  - 10.1016/j.lungcan.2026.109581
UR  - https://doi.org/10.1016/j.lungcan.2026.109581
ER  -

APA

G, M., PE, L., L, S., BC, C., U, D., S, A., M, G., S, P., A, L., B, Z., Y, Y., TE, C., MJ, A., J, M., M, S., F, B., T, Y., F, D., J, W., S, H., D, G., & CM, R. (2026). Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.. Lung cancer (Amsterdam, Netherlands). https://doi.org/10.1016/j.lungcan.2026.109581

Source records

pubmed · retrieved 2026-09-25T17:47:21.917Z